On February 12, Shanghai Yizhong Pharmaceutical Co.Ltd(688091) and Qingdao Baheal Medical Inc(301015) signed a cooperation agreement in Qingdao. The two sides will cooperate on the commercialization of Shanghai Yizhong Pharmaceutical Co.Ltd(688091) ‘s tumor innovative drug “paclitaxel polymer micelles for injection” (hereinafter referred to as “paclitaxel micelles”) Zisheng, so as to jointly promote the accessibility of domestic tumor innovative drugs and benefit many tumor patients in China.
It is reported that paclitaxel products, as the cornerstone drugs of anti-tumor chemotherapy, have a wide range of indications, exact curative effect and large clinical demand. It is one of the most widely used heavy star drugs of anti-tumor chemotherapy in China. So far, it has developed for 30 years. Shanghai Yizhong Pharmaceutical Co.Ltd(688091) Zisheng, the “paclitaxel polymer micelle for injection” independently developed, is the latest dosage form of class 2.2 third-generation paclitaxel approved by the State Food and Drug Administration (nmpa) (an innovative dosage form not listed at home and abroad), and it is also the first paclitaxel micelle approved to be listed in China, Its phase III clinical research was approved by the first batch of projects in the 13th five year plan, a major scientific and technological project of the national “major new drug creation”. Compared with other paclitaxel dosage forms on the market, paclitaxel micelles have relatively better safety when the clinical dosage is greatly increased; The clinical trial results of non-small cell lung cancer (NSCLC) showed that the objective remission rate (ORR) of paclitaxel micelles was significantly improved, and the progression free survival (PFS) was significantly prolonged. The efficacy and safety of paclitaxel micelles showed their unique advantages and advancement in the first-line treatment of advanced non-small cell lung cancer, and would become a new choice for chemotherapy of non-small cell lung cancer.
At the signing ceremony, Zhou Jinsong, chairman of Shanghai Yizhong Pharmaceutical Co.Ltd(688091) , said: ” Shanghai Yizhong Pharmaceutical Co.Ltd(688091) is committed to developing a new generation of innovative drugs to provide patients with safe, effective and affordable high-quality drugs to meet the urgent treatment needs. Paclitaxel micelles are our first listed products. We hope to cooperate with Qingdao Baheal Medical Inc(301015) in the commercialization stage Such a professional third-party commercial platform cooperates to jointly promote innovative drug products to enter the market and benefit more cancer patients. “
Fu Gang, chairman of Qingdao Baheal Medical Inc(301015) , said: ” Qingdao Baheal Medical Inc(301015) As a third-party commercial platform with brand operation as the core, it has strict selection standards. The first is to select products that can really optimize the clinical application scenario. The second is to evaluate the technical barriers of products based on professional evaluation ability to avoid falling into the dilemma of low-level repetition. The third is to do a good job in factor allocation with ecological coordination and select products that can truly complement and cooperate with Baiyang resources for commercial operation. “
“Paclitaxel micelle Zisheng is the third generation of paclitaxel, which has significant curative effect and good safety. It is a revolutionary product. Qingdao Baheal Medical Inc(301015) will do a good job in factor configuration according to the characteristics of its life cycle, formulate reasonable commercial solutions and help the product release value.” Fu Gang further said.
